These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23785525)

  • 1. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia.
    Harding-Esch EM; Sillah A; Edwards T; Burr SE; Hart JD; Joof H; Laye M; Makalo P; Manjang A; Molina S; Sarr-Sissoho I; Quinn TC; Lietman T; Holland MJ; Mabey D; West SK; Bailey R;
    PLoS Negl Trop Dis; 2013; 7(6):e2115. PubMed ID: 23785525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study.
    Harding-Esch E; Jofre-Bonet M; Dhanjal JK; Burr S; Edwards T; Holland M; Sillah A; West S; Lietman T; Keenan J; Mabey D; Bailey R
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003670. PubMed ID: 25901349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
    Yohannan J; Munoz B; Mkocha H; Gaydos CA; Bailey R; Lietman TA; Quinn T; West SK
    JAMA Ophthalmol; 2013 Apr; 131(4):431-6. PubMed ID: 23392481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a single round of mass drug administration with azithromycin on active trachoma and ocular Chlamydia trachomatis prevalence and circulating strains in The Gambia and Senegal.
    Harding-Esch EM; Holland MJ; Schémann JF; Sillah A; Sarr B; Christerson L; Pickering H; Molina-Gonzalez S; Sarr I; Andreasen AA; Jeffries D; Grundy C; Mabey DCW; Herrmann B; Bailey RL
    Parasit Vectors; 2019 Oct; 12(1):497. PubMed ID: 31640755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa.
    Last AR; Burr SE; Harding-Esch E; Cassama E; Nabicassa M; Roberts CH; Mabey DCW; Holland MJ; Bailey RL
    Parasit Vectors; 2017 Dec; 10(1):624. PubMed ID: 29282126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged children.
    Lee JS; Muñoz BE; Mkocha H; Gaydos CA; Quinn TC; West SK
    PLoS Negl Trop Dis; 2014 Apr; 8(4):e2761. PubMed ID: 24722392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma.
    West SK; Bailey R; Munoz B; Edwards T; Mkocha H; Gaydos C; Lietman T; Porco T; Mabey D; Quinn TC
    PLoS Negl Trop Dis; 2013; 7(8):e2415. PubMed ID: 24009792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia.
    Stare D; Harding-Esch E; Munoz B; Bailey R; Mabey D; Holland M; Gaydos C; West S
    Ophthalmic Epidemiol; 2011 Feb; 18(1):20-9. PubMed ID: 21275593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.
    West SK; Munoz B; Mkocha H; Gaydos C; Quinn T
    Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1492-7. PubMed ID: 17389476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II).
    Keenan JD; Tadesse Z; Gebresillasie S; Shiferaw A; Zerihun M; Emerson PM; Callahan K; Cotter SY; Stoller NE; Porco TC; Oldenburg CE; Lietman TM
    PLoS Med; 2018 Aug; 15(8):e1002633. PubMed ID: 30106956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotics for trachoma.
    Evans JR; Solomon AW; Kumar R; Perez Á; Singh BP; Srivastava RM; Harding-Esch E
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD001860. PubMed ID: 31554017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One round of azithromycin MDA adequate to interrupt transmission in districts with prevalence of trachomatous inflammation-follicular of 5.0-9.9%: Evidence from Malawi.
    Kalua K; Chisambi A; Chinyanya D; Masika M; Bakhtiari A; Willis R; Emerson PM; Solomon AW; Bailey RL
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006543. PubMed ID: 29897902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profound and sustained reduction in Chlamydia trachomatis in The Gambia: a five-year longitudinal study of trachoma endemic communities.
    Burton MJ; Holland MJ; Makalo P; Aryee EA; Sillah A; Cohuet S; Natividad A; Alexander ND; Mabey DC; Bailey RL
    PLoS Negl Trop Dis; 2010 Oct; 4(10):. PubMed ID: 20957147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation (ASANTE) Trial: Design and Baseline Characteristics.
    Ervin AM; Mkocha H; Munoz B; Dreger K; Dize L; Gaydos C; Quinn TC; West SK
    Ophthalmic Epidemiol; 2016 Dec; 23(6):347-353. PubMed ID: 27820670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities.
    Wilson N; Goodhew B; Mkocha H; Joseph K; Bandea C; Black C; Igietseme J; Munoz B; West SK; Lammie P; Kasubi M; Martin DL
    Ophthalmic Epidemiol; 2019 Feb; 26(1):1-6. PubMed ID: 30543311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community-level Association between Clinical Trachoma and Ocular Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of Niger.
    Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Porco TC; Keenan JD; Lietman TM; Oldenburg CE
    Ophthalmic Epidemiol; 2019 Aug; 26(4):231-237. PubMed ID: 30957594
    [No Abstract]   [Full Text] [Related]  

  • 17. Cohort and age effects of mass drug administration on prevalence of trachoma: a longitudinal study in rural Tanzania.
    Shekhawat N; Mkocha H; Munoz B; Gaydos C; Dize L; Quinn TC; West SK
    Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2307-14. PubMed ID: 24448262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stopping azithromycin mass drug administration for trachoma: A systematic review.
    Mahmud H; Landskroner E; Amza A; Aragie S; Godwin WW; de Hostos Barth A; O'Brien KS; Lietman TM; Oldenburg CE
    PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009491. PubMed ID: 34237074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azithromycin Reduction to Reach Elimination of Trachoma (ARRET): study protocol for a cluster randomized trial of stopping mass azithromycin distribution for trachoma.
    Amza A; Kadri B; Nassirou B; Arzika AM; Austin A; Nyatigo F; Lebas E; Arnold BF; Lietman TM; Oldenburg CE
    BMC Ophthalmol; 2021 Jan; 21(1):15. PubMed ID: 33407263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution.
    King JD; Teferi T; Cromwell EA; Zerihun M; Ngondi JM; Damte M; Ayalew F; Tadesse Z; Gebre T; Mulualem A; Karie A; Melak B; Adugna M; Gessesse D; Worku A; Endashaw T; Admassu Ayele F; Stoller NE; King MR; Mosher AW; Gebregzabher T; Haileysus G; Odermatt P; Utzinger J; Emerson PM
    PLoS Negl Trop Dis; 2014 Mar; 8(3):e2732. PubMed ID: 24625539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.